Pneumococcal Vaccine Global Market Opportunities And Strategies To 2034

Name: Pneumococcal Vaccine Global Market Opportunities And Strategies To 2034
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

Download Sample Buy Report

Pneumococcal Vaccine Market 2025 – By Product Type (Pneumococcal Conjugate Vaccine (PCVs), Pneumococcal Polysaccharide Vaccine (PPV)), By Route Of Administration (Intramuscular, Subcutaneous), By Distribution Channel (Pharmacies, Community Clinics, Public Health Agencies, Other Distribution Channels), By End User (Pediatrics, Adults), And By Region, Opportunities And Strategies – Global Forecast To 2035

Pneumococcal Vaccine Global Market Opportunities And Strategies To 2034

Report Price : $4490.00 | Pages : 338 | Published : September 2025 | Delivery Time: Immediately | Format :

Purchase Options

Request a Sample

Request For Discount

Customise Your Report

Item added to cart!

Request For Regional Data

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Pneumococcal Vaccine Market Definition

Pneumococcal vaccines (PCV) are immunizations designed to protect against infections caused by Streptococcus pneumoniae, a bacterium responsible for illnesses such as pneumonia, meningitis, sinusitis, and bloodstream infections. The primary purpose of pneumococcal vaccine is to prevent serious and potentially life-threatening pneumococcal diseases, especially in high-risk groups like infants, older adults, and people with chronic illnesses.

The pneumococcal vaccine market consists of sales by entities (organizations, sole traders and partnerships) of pneumococcal vaccine that are deployed at scheduled intervals, with infant PCV doses at 2, 4, 6 and 12 months, with adult booster doses as recommended by bodies such as the Centers for Disease Control and Prevention (CDC), the US based national public health agency.

Pneumococcal Vaccine Global Market Opportunities And Strategies To 2034 Market Size and growth rate 2025 to 2029: Graph

Pneumococcal Vaccine Market Size

The global pneumococcal vaccine market reached a value of nearly $7,927.45 million in 2024, having grown at a compound annual growth rate (CAGR) of 4.17% since 2019. The market is expected to grow from $7,927.45 million in 2024 to $10,041.97 million in 2029 at a rate of 4.84%. The market is then expected to grow at a CAGR of 4.33% from 2029 and reach $12,411.73 million in 2034.

Growth in the historic period resulted from the increasing prevalence of pneumococcal contamination, rising healthcare spending, growing awareness of preventive healthcare and increased government immunization programs. Factors that negatively affected growth in the historic period was stringent regulatory requirements and vaccine hesitancy and misinformation.

Going forward, the growing aging population, rising prevalence of chronic respiratory diseases, rising need for pediatric vaccination and growing public health campaigns will drive the growth. Factor that could hinder the growth of the pneumococcal vaccine market in the future include cold chain and storage challenge high cost of vaccines and impact of trade war and tariff.

Pneumococcal Vaccine Market Drivers

The key drivers of the pneumococcal vaccine market include:

Growing Aging Population

During the forecast period, the growing aging population is expected to propel the growth of the pneumococcal vaccine market. The aging global population is creating a larger at-risk group for pneumococcal infections such as pneumonia and meningitis, due to age-related immune decline, leading to a sustained rise in vaccine demand. In response, healthcare systems and governments are prioritizing preventive measures to lower elderly morbidity and long-term care costs. Pneumococcal vaccination is central to these strategies, strengthening both public immunization campaigns and private healthcare recommendations, thereby driving overall market growth. Additionally, many countries are expanding adult and senior immunization programs, particularly in regions such as North America, Europe and Asia. These programs increasingly incorporate pneumococcal vaccine as a routine preventive measure. This integrated approach is accelerating vaccine adoption across the aging population segment. The growing aging population growth contribution during the forecast period in 2024 is 1.50%.

Pneumococcal Vaccine Market Restraints

The key restraints on the pneumococcal vaccine market include:

Cold Chain And Storage Challenges

The cold chain and storage challenges are expected to restrict the growth of the pneumococcal vaccine market, during the forecast period. Pneumococcal vaccines require strict cold chain storage between 2°C and 8°C to maintain efficacy, but poor refrigeration infrastructure in low- and middle-income regions often hinders proper handling. Maintaining this cold chain demands high logistical investment in equipment like refrigerated vehicles and temperature monitors and escalating distribution costs. In remote or underdeveloped areas lacking reliable electricity, consistent storage is challenging, limiting vaccine access and coverage. Geographic and infrastructure barriers further reduce immunization rates in hard-to-reach populations. Additionally, cold chain failures can lead to significant vaccine spoilage, causing financial losses and disrupting immunization efforts. This risk often deters large-scale stockpiling or outreach initiatives. Growth affected by cold chain and storage challenges during the forecast period in 2024 is -2.00%.

Pneumococcal Vaccine Market Trends

Major trends shaping the pneumococcal vaccine market include:

Innovative Pneumococcal Vaccine Enhances Pediatric Immunization By Targeting Local Disease Burden

Companies operating in the pneumococcal vaccine market are focusing on developing innovative formulations tailored to regional disease patterns and immune response optimization. These advancements aim to improve vaccine effectiveness, address local public health needs and reduce dependence on imported products. For example, in June 2025, CanSino Biologics Inc. (CanSinoBIO) is a China-based biopharmaceutical company launched its pneumococcal conjugate vaccine—iPneucia, a 13 valent formulation tailored to China’s epidemiological needs. Designed with innovative dual carriers Cross-Reacting Material 197 (CRM197 + tetanus toxoid), it enhances immunogenicity while minimizing interference with other vaccines. Clinical data show strong antibody responses against key serotypes prevalent in Chinese children. As a domestically developed alternative to imported vaccines, iPneucia supports national immunization efforts, improves access and strengthens CanSinoBIO’s position in the pediatric vaccine market.

Innovative Conjugate Vaccines Aim To Bridge Global Immunization Gaps

Leading companies in the pneumococcal vaccine market are prioritizing the development of next-generation vaccines with broader serotype coverage and enhanced immune responses. These innovations are designed to address regional variations in disease burden and emerging bacterial strains, with the goal of closing immunization gaps and providing stronger protection for both children and adults. For example, in November 2024, Abbott, a US-based healthcare and medical devices company launched PneumoShield 14, a 14-valent pneumococcal conjugate vaccine (PCV-14) in India, offering the broadest protection for children against pneumococcal bacterial infections. Targeted at children aged six weeks and older, the vaccine covers 14 key serotypes responsible for severe diseases such as pneumonia, meningitis and sepsis. It is administered in three doses at 6, 10 and 14 weeks of age. Compared to existing PCV-10 and PCV-13 vaccines, PneumoShield 14 provides broader coverage and addresses serotypes more prevalent in India. This launch reinforces Abbott’s commitment to strengthening pediatric immunization and improving child health outcomes in high-burden regions.

Opportunities And Recommendations In The Pneumococcal Vaccine Market

Opportunities – The top opportunities in the pneumococcal vaccine market segmented by product type will arise in the pneumococcal conjugate vaccine (PCVs) segment, which will gain $2,185.82 million of global annual sales by 2029. The top opportunities in the pneumococcal vaccine market segmented by route of administration will arise in the intramuscular segment, which will gain $2,132.34 million of global annual sales by 2029. The top opportunities in the pneumococcal vaccine market segmented by distribution channel will arise in the public health agencies segment, which will gain $1,431.99 million of global annual sales by 2029. The top opportunities in the pneumococcal vaccine market segmented by end user will arise in the pediatrics segment, which will gain $1,433.34 million of global annual sales by 2029. The pneumococcal vaccine market size will gain the most in the USA at $983.14 million.

Recommendations- To take advantage of the opportunities, The Business Research Company recommends the pneumococcal vaccine companies to focus on region-specific innovation to drive market penetration, focus on expanding serotype coverage to address regional disease burdens, focus on strengthening product pipelines through targeted R&D investment, focus on adult-specific vaccine development to expand market coverage, focus on advancing conjugate vaccines to improve protection across age groups, focus on expanding pneumococcal conjugate vaccine offerings, focus on scaling intramuscular vaccine delivery, expand in emerging markets, focus on strategic partnerships to strengthen market position and accelerate access, focus on competitive and value-based pricing to maximize market penetration, focus on targeted digital and traditional promotion channels, focus on partnerships and healthcare provider training, focus on strengthening public health agency partnerships and focus on capturing growth in the adult segment.

Book your 30 minutes free consultation with our research experts

Pneumococcal Vaccine Market Segmentation

The pneumococcal vaccine market is segmented by product type, by route of administration, by distribution channel and by end user.

By Product Type –

The pneumococcal vaccine market is segmented by product type into:

a) Pneumococcal Conjugate Vaccine (PCVs)

b) Pneumococcal Polysaccharide Vaccine (PPV)

The pneumococcal conjugate vaccine (PCVs) market was the largest segment of the pneumococcal vaccine market segmented by product type, accounting for 96.68% or $7,664.45 million of the total in 2024. Going forward, the pneumococcal conjugate vaccine (PCVs) segment is expected to be the fastest growing segment in the pneumococcal vaccine market segmented by product type, at a CAGR of 5.15% during 2024-2029.

By Route of Administration –

The pneumococcal vaccine market is segmented by route of administration into:

a) Intramuscular

b) Subcutaneous

The platforms market was the largest segment of the pneumococcal vaccine market segmented by component, accounting for 61.30% or $4,490.50 million of the total in 2024. Going forward, the platforms segment is expected to be the fastest growing segment in the pneumococcal vaccine market segmented by component, at a CAGR of 15.78% during 2024-2029.

By Distribution Channel –

The pneumococcal vaccine market is segmented by distribution channel into:

a) Pharmacies

b) Community Clinics

c) Public Health Agencies

d) Other Distribution Channels

The public health agencies market was the largest segment of the pneumococcal vaccine market segmented by distribution channel, accounting for 47.33% or $3,751.95 million of the total in 2024. Going forward, the public health agencies segment is expected to be the fastest growing segment in the pneumococcal vaccine market segmented by distribution channel, at a CAGR of 6.68% during 2024-2029.

By End User –

The pneumococcal vaccine market is segmented by end user into:

a) Pediatrics

b) Adults

The pediatrics market was the largest segment of the pneumococcal vaccine market segmented by end user, accounting for 77.70% or $6,159.50 million of the total in 2024. Going forward, the adults segment is expected to be the fastest growing segment in the pneumococcal vaccine market segmented by end user, at a CAGR of 6.74% during 2024-2029.

By Geography - The pneumococcal vaccine market is segmented by geography into:

o Asia Pacific

• China

• India

• Japan

• Australia

• Indonesia

• South Korea

o North America

• USA

• Canada

o South America

• Brazil

o Western Europe

• France

• Germany

• UK

• Italy

• Spain

o Eastern Europe

• Russia

o Middle East

o Africa

North America was the largest region in the pneumococcal vaccine market, accounting for 52.01% or $4,123.11 million of the total in 2024. It was followed by Asia-Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the pneumococcal vaccine market will be Asia-Pacific and South America where growth will be at CAGRs of 6.31% and 5.71% respectively. These will be followed by Eastern Europe and Middle East where the markets are expected to grow at CAGRs of 5.35% and 4.57% respectively.

Pneumococcal Vaccine Market Competitive Landscape

Major Competitors are:

Pfizer Inc.

Merck & Co. Inc.

GlaxoSmithKline plc

Serum Institute of India Pvt. Ltd.

Walvax Biotechnology Co. Ltd.

Other Competitors Include:

Biological E. Limited

SK Bioscience Co., Ltd.

Sanofi

GSK

Anhui Zhifei Longcom Biopharmaceutical Co. Ltd.

Hualan Biological Engineering Inc.

Beijing Minhai Biotechnology Limited Company

Panacea Biotec

Tergene Biotech

CanSinoBIO

Abbott India Ltd.

PnuVax Incorporated

Nanolek

NPO Petrovax Pharm LLC

Sinergium Biotech

Author: Abdul Wasay

1 Executive Summary

1.1 Pneumococcal Vaccine – Market Attractiveness And Macro Economic Landscape

2 Table Of Contents

3 List Of Tables

4 List Of Figures

5 Report Structure

6 Market Characteristics

6.1 General Market Definition

6.2 Summary

6.3 Pneumococcal Vaccine Market Definition And Segmentations

6.4 Market Segmentation By Product Type

6.4.1 Pneumococcal Conjugate Vaccine (PCVs)

6.4.2 Pneumococcal Polysaccharide Vaccine (PPV)

6.5 Market Segmentation By Route of Administration

6.5.1 Intramuscular

6.5.2 Subcutaneous

6.6 Market Segmentation By Distribution Channel

6.6.1 Pharmacies

6.6.2 Community Clinics

6.6.3 Public Health Agencies

6.6.4 Other Distribution Channels

6.7 Market Segmentation By End User

6.7.1 Pediatrics

6.7.2 Adults

7 Major Market Trends

7.1 Innovative Pneumococcal Vaccine Enhances Pediatric Immunization By Targeting Local Disease Burden

7.2 Innovative Conjugate Vaccines Aim To Bridge Global Immunization Gaps

7.3 Strategic Collaborations Accelerate Pneumococcal Vaccine Access

7.4 New Investment Wave Supports Scalable Pneumococcal Immunization

7.5 Advancing Adult Immunization Through Serotype-Specific Vaccines

7.6 Advances In Conjugate Vaccine Technology Improve Adult Immunity

8 Pneumococcal Vaccine Growth Analysis And Strategic Analysis Framework

8.1 Pneumococcal Vaccine PESTEL Analysis

8.1.1 Political

8.1.2 Economic

8.1.3 Social

8.1.4 Technological

8.1.5 Environmental

8.1.6 Legal

8.2 Analysis Of End User (B2B and B2C)

8.2.1 Pediatrics

8.2.2 Adults

8.3 Pneumococcal Vaccine Market Growth Rate Analysis

8.4 Global Historic Market Growth, 2019 – 2024, Value ($ Million)

8.4.1 Market Drivers 2019 – 2024

8.4.2 Market Restraints 2019 – 2024

8.5 Global Forecast Market Growth, 2024 – 2029, 2034F Value ($ Million)

8.6 Forecast Growth Contributors/Factors

8.6.1 Quantitative Growth Contributors

8.6.2 Drivers

8.6.3 Restraints

8.7 Global Pneumococcal Vaccine Total Addressable Market (TAM)

9 Pneumococcal Vaccine Market Segmentation

9.1 Global Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

9.2 Global Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

9.3 Global Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

9.4 Global Pneumococcal Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

9.5 Global Pneumococcal Vaccine Market, Sub-Segmentation Of Pneumococcal Conjugate Vaccines (PCVs), By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

9.6 Global Pneumococcal Vaccine Market, Sub-Segmentation Of Pneumococcal Polysaccharide Vaccine (PPV), By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

10 Pneumococcal Vaccine Market, Regional and Country Analysis

10.1 Pneumococcal Vaccine Market, By Region, Historic and Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

10.2 Pneumococcal Vaccine Market, By Country, Historic and Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

11 Asia-Pacific Market

11.1 Summary

11.2 Market Overview

11.2.1 Region Information

11.2.2 Market Information

11.2.3 Background Information

11.2.4 Government Initiatives

11.2.5 Regulations

11.2.6 Regulatory Bodies

11.2.7 Major Associations

11.2.8 Taxes Levied

11.2.9 Corporate Tax Structure

11.2.10 Investments

11.2.11 Major Companies

11.3 Asia-Pacific Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

11.4 Asia-Pacific Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

11.5 Asia-Pacific Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

11.6 Asia-Pacific Pneumococcal Vaccine Market: Country Analysis

11.7 China Market

11.8 Summary

11.9 Market Overview

11.9.1 Country Information

11.9.2 Market Information

11.9.3 Background Information

11.9.4 Government Initiatives

11.9.5 Regulations

11.9.6 Regulatory Bodies

11.9.7 Major Associations

11.9.8 Taxes Levied

11.9.9 Corporate Tax Structure

11.9.10 Investments

11.9.11 Major Companies

11.10 China Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

11.11 China Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

11.12 China Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

11.13 India Market

11.14 India Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

11.15 India Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

11.16 India Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

11.17 Japan Market

11.18 Summary

11.19 Market Overview

11.19.1 Country Information

11.19.2 Market Information

11.19.3 Background Information

11.19.4 Government Initiatives

11.19.5 Regulatory Bodies

11.19.6 Major Associations

11.19.7 Taxes Levied

11.19.8 Corporate Tax Structure

11.19.9 Investments

11.19.10 Major Companies

11.20 Japan Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

11.21 Japan Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

11.22 Japan Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

11.23 Australia Market

11.24 Australia Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

11.25 Australia Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

11.26 Australia Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

11.27 Indonesia Market

11.28 Indonesia Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

11.29 Indonesia Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

11.30 Indonesia Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

11.31 South Korea Market

11.32 Summary

11.33 Market Overview

11.33.1 Country Information

11.33.2 Market Information

11.33.3 Background Information

11.33.4 Government Initiatives

11.33.5 Regulations

11.33.6 Regulatory Bodies

11.33.7 Major Associations

11.33.8 Taxes Levied

11.33.9 Corporate Tax Structure

11.33.10 Investments

11.33.11 Major Companies

11.34 South Korea Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

11.35 South Korea Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

11.36 South Korea Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

12 Western Europe Market

12.1 Summary

12.2 Market Overview

12.2.1 Region Information

12.2.2 Market Information

12.2.3 Background Information

12.2.4 Government Initiatives

12.2.5 Regulations

12.2.6 Regulatory Bodies

12.2.7 Major Associations

12.2.8 Taxes Levied

12.2.9 Corporate tax structure

12.2.10 Investments

12.2.11 Major Companies

12.3 Western Europe Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

12.4 Western Europe Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

12.5 Western Europe Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

12.6 Western Europe Pneumococcal Vaccine Market: Country Analysis

12.7 UK Market

12.8 UK Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

12.9 UK Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

12.10 UK Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

12.11 Germany Market

12.12 Germany Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

12.13 Germany Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

12.14 Germany Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

12.15 France Market

12.16 France Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

12.17 France Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

12.18 France Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

12.19 Italy Market

12.20 Italy Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

12.21 Italy Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

12.22 Italy Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

12.23 Spain Market

12.24 Spain Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

12.25 Spain Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

12.26 Spain Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

13 Eastern Europe Market

13.1 Summary

13.2 Market Overview

13.2.1 Region Information

13.2.2 Market Information

13.2.3 Background Information

13.2.4 Government Initiatives

13.2.5 Regulations

13.2.6 Regulatory Bodies

13.2.7 Major Associations

13.2.8 Taxes Levied

13.2.9 Corporate Tax Structure

13.2.10 Investments

13.2.11 Major Companies

13.3 Eastern Europe Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

13.4 Eastern Europe Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

13.5 Eastern Europe Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

13.6 Eastern Europe Pneumococcal Vaccine Market: Country Analysis

13.7 Russia Market

13.8 Russia Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

13.9 Russia Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

13.10 Russia Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

14 North America Market

14.1 Summary

14.2 Market Overview

14.2.1 Region Information

14.2.2 Market Information

14.2.3 Background Information

14.2.4 Government Initiatives

14.2.5 Regulations

14.2.6 Regulatory Bodies

14.2.7 Major Associations

14.2.8 Taxes Levied

14.2.9 Corporate Tax Structure

14.2.10 Investments

14.2.11 Major Companies

14.3 North America Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

14.4 North America Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

14.5 North America Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

14.6 North America Pneumococcal Vaccine Market: Country Analysis

14.7 USA Market

14.8 Summary

14.9 Market Overview

14.9.1 Country Information

14.9.2 Market Information

14.9.3 Background Information

14.9.4 Government Initiatives

14.9.5 Regulations

14.9.6 Regulatory Bodies

14.9.7 Major Associations

14.9.8 Taxes Levied

14.9.9 Corporate Tax Structure

14.9.10 Investments

14.9.11 Major Companies

14.10 USA Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

14.11 USA Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

14.12 USA Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

14.13 Canada Market

14.14 Summary

14.15 Market Overview

14.15.1 Country Information

14.15.2 Market Information

14.15.3 Background Information

14.15.4 Government Initiatives

14.15.5 Regulations

14.15.6 Regulatory Bodies

14.15.7 Major Associations

14.15.8 Taxes Levied

14.15.9 Corporate Tax Structure

14.15.10 Investments

14.15.11 Major Companies

14.16 Canada Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

14.17 Canada Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

14.18 Canada Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

15 South America Market

15.1 Summary

15.2 Market Overview

15.2.1 Region Information

15.2.2 Market Information

15.2.3 Background Information

15.2.4 Government Initiatives

15.2.5 Regulations

15.2.6 Regulatory Bodies

15.2.7 Major Associations

15.2.8 Taxes Levied

15.2.9 Corporate Tax Structure

15.2.10 Investments

15.2.11 Major Companies

15.3 South America Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

15.4 South America Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

15.5 South America Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

15.6 South America Pneumococcal Vaccine Market: Country Analysis

15.7 Brazil Market

15.8 Brazil Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

15.9 Brazil Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

15.10 Brazil Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

16 Middle East Market

16.1 Summary

16.2 Market Overview

16.2.1 Region Information

16.2.2 Market Information

16.2.3 Background Information

16.2.4 Government Initiatives

16.2.5 Regulations

16.2.6 Regulatory Bodies

16.2.7 Major Associations

16.2.8 Taxes Levied

16.2.9 Corporate Tax Structure

16.2.10 Investments

16.2.11 Major Companies

16.3 Middle East Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

16.4 Middle East Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

16.5 Middle East Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

17 Africa Market

17.1 Summary

17.2 Market Overview

17.2.1 Region Information

17.2.2 Market Information

17.2.3 Background Information

17.2.4 Government Initiatives

17.2.5 Regulations

17.2.6 Regulatory Bodies

17.2.7 Major Associations

17.2.8 Taxes Levied

17.2.9 Corporate Tax Structure

17.2.10 Investments

17.2.11 Major Companies

17.3 Africa Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

17.4 Africa Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

17.5 Africa Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

18 Competitive Landscape And Company Profiles

18.1 Company Profiles

18.2 Pfizer Inc

18.2.1 Company Overview

18.2.2 Products And Services

18.2.3 Business Strategy

18.2.4 Financial Overview

18.3 Merck & Co., Inc.

18.3.1 Company Overview

18.3.2 Products And Services

18.3.3 Business Strategy

18.3.4 Financial Overview

18.4 GlaxoSmithKline plc

18.4.1 Company Overview

18.4.2 Products And Services

18.4.3 Financial Overview

18.5 Serum Institute of India Pvt. Ltd

18.5.1 Company Overview

18.5.2 Products And Services

18.5.3 Business Strategy

18.5.4 Financial Overview

18.6 Walvax Biotechnology Co. Ltd

18.6.1 Company Overview

18.6.2 Products And Services

18.6.3 Financial Overview

19 Other Major And Innovative Companies

19.1 Biological E. Limited

19.1.1 Company Overview

19.1.2 Products And Services

19.2 Anhui Zhifei Longcom Biopharmaceutical Co. Ltd.

19.2.1 Company Overview

19.2.2 Products And Services

19.3 Shenzhen Kangtai Biological Products Co. Ltd. (Beijing Minhai Biotechnology Corporation Limited)

19.3.1 Company Overview

19.3.2 Products And Services

19.4 NPO Petrovax Pharm LLC

19.4.1 Company Overview

19.4.2 Products And Services

19.5 SK Bioscience Co. Ltd.

19.5.1 Company Overview

19.5.2 Products And Services

19.6 Vaxcyte, Inc.

19.6.1 Company Overview

19.6.2 Products And Services

19.7 Sinovac Biotech Ltd.

19.7.1 Company Overview

19.7.2 Products And Services

19.8 Astellas Pharma Inc.

19.8.1 Company Overview

19.8.2 Products And Services

19.9 LG Chem Ltd.

19.9.1 Company Overview

19.9.2 Products And Services

19.10 AIM Vaccine Co. Ltd.

19.10.1 Company Overview

19.10.2 Products And Services

19.11 Panacea Biotec Limited

19.11.1 Company Overview

19.11.2 Products And Services

19.12 China National Biotec Group (CNBG)

19.12.1 Company Overview

19.12.2 Products And Services

19.13 Inventprise LLC

19.13.1 Company Overview

19.13.2 Products And Services

19.14 Pnuvax Incorporated

19.14.1 Company Overview

19.14.2 Products And Services

19.15 Tergene Biotech Private Limited

19.15.1 Company Overview

19.15.2 Products And Services

20 Competitive Benchmarking

21 Competitive Dashboard

22 Key Mergers And Acquisitions

22.1 SK bioscience Co. Ltd Acquired Fina Biosolutions

22.2 GSK Plc Acquired Affinivax

23 Recent Developments In The Pneumococcal Vaccine Market

23.1 New Pneumococcal Vaccine Launch Targets Nationwide Adult Protection

23.2 Next-Generation Pneumococcal Vaccine Approval Targets Drug-Resistant Strains

24 Opportunities And Strategies

24.1 Pneumococcal Vaccine Market In 2029 – Countries Offering Most New Opportunities

24.2 Pneumococcal Vaccine Market In 2029 – Segments Offering Most New Opportunities

24.3 Pneumococcal Vaccine Market In 2029 – Growth Strategies

24.3.1 Market Trend Based Strategies

24.3.2 Competitor Strategies

25 Pneumococcal Vaccine Market, Conclusions And Recommendations

25.1 Conclusions

25.2 Recommendations

25.2.1 Product

25.2.2 Place

25.2.3 Price

25.2.4 Promotion

25.2.5 People

26 Appendix

26.1 Geographies Covered

26.2 Market Data Sources

26.3 Research Methodology

26.4 Currencies

26.5 The Business Research Company

26.6 Copyright and Disclaimer

List Of Tables

Table 1: Pneumococcal Vaccine Market, Historic, 2019 – 2024, $ Million

Table 2: Pneumococcal Vaccine Market, Forecast, 2024 – 2029, 2034F, $ Million

Table 3: Global Pneumococcal Vaccine Market TAM, 2024 And 2034, $ Million

Table 4: Global Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 5: Global Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 6: Global Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 7: Global Pneumococcal Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 8: Global Pneumococcal Vaccine Market, Sub-Segmentation Of Pneumococcal Conjugate Vaccines (PCVs), By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 9: Global Pneumococcal Vaccine Market, Sub-Segmentation Of Pneumococcal Polysaccharide Vaccine (PPV), By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 10: Pneumococcal Vaccine Market, By Region, Historic and Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 11: Pneumococcal Vaccine Market, By Country, Historic and Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 12: Asia-Pacific GDP Per Capita, By Country, 2019-2024, $

Table 13: Asia-Pacific Population, By Country, 2019-2029, Millions

Table 14: Asia-Pacific Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 15: Asia-Pacific Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 16: Asia-Pacific Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 17: China GDP Per Capita, 2019-2024, $

Table 18: China Population, 2019-2029, Millions

Table 19: China Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 20: China Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 21: China Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 22: India Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 23: India Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 24: India Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 25: Japan GDP Per Capita, 2019-2024, $

Table 26: Japan Population, By Country, 2019-2029, Millions

Table 27: Japan Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 28: Japan Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 29: Japan Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 30: Australia Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 31: Australia Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 32: Australia Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 33: Indonesia Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 34: Indonesia Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 35: Indonesia Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 36: South Korea GDP Per Capita, 2019-2024, $

Table 37: South Korea Population, 2019-2029, Millions

Table 38: South Korea Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 39: South Korea Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 40: South Korea Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 41: Western Europe GDP Per Capita, By Country, 2019-2024, $

Table 42: Western Europe Population, By Country, 2019-2029, Millions

Table 43: Western Europe Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 44: Western Europe Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 45: Western Europe Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 46: UK Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 47: UK Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 48: UK Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 49: Germany Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 50: Germany Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 51: Germany Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 52: France Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 53: France Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 54: France Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 55: Italy Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 56: Italy Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 57: Italy Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 58: Spain Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 59: Spain Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 60: Spain Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 61: Eastern Europe GDP Per Capita, By Country, 2019-2024, $

Table 62: Eastern Europe Population, By Country, 2019-2029, Millions

Table 63: Eastern Europe Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 64: Eastern Europe Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 65: Eastern Europe Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 66: Russia Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 67: Russia Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 68: Russia Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 69: North America GDP Per Capita, By Country, 2019-2024, $

Table 70: North America Population, By Country, 2019-2029, Millions

Table 71: North America Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 72: North America Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 73: North America Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 74: USA GDP Per Capita, 2019-2024, $

Table 75: USA Population, 2019-2029, Millions

Table 76: USA Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 77: USA Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 78: USA Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 79: Canada GDP Per Capita, 2019-2024, $

Table 80: Canada Population, By Country, 2019-2029, Millions

Table 81: Canada Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 82: Canada Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 83: Canada Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 84: South America GDP Per Capita, By Country, 2019-2024, $

Table 85: South America Population, By Country, 2019-2029, Millions

Table 86: South America Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 87: South America Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 88: South America Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 89: Brazil Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 90: Brazil Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 91: Brazil Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 92: Middle East GDP Per Capita, By Country, 2019-2024, $

Table 93: Middle East Population, By Country, 2019-2029, Millions

Table 94: Middle East Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 95: Middle East Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 96: Middle East Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 97: Africa GDP Per Capita, By Country, 2019-2024, $

Table 98: Africa Population, By Country, 2019-2029, Millions

Table 99: Africa Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 100: Africa Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 101: Africa Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 102: Global Pneumococcal Vaccine Market, Key Competitor Estimated Market Shares, 2023, Percentage (%)

Table 103: Pfizer Inc – Financial Overview, 2019 – 2023, $Billion

Table 104: Merck & Co., Inc – Financial Overview, 2019 – 2023, $Billion

Table 105: GlaxoSmithKline plc – Financial Overview, 2019 – 2023, $ Billion

Table 106: Serum Institute of India Pvt. Ltd – Financial Overview, 2023, $Billion

Table 107: Walvax Biotechnology Co. Ltd – Financial Overview, 2023, $Million

Table 108: Pneumococcal Vaccine Market, Competitive Benchmarking (In USD Millions)

Table 109: Pneumococcal Vaccine Market, Competitive Dashboard

Table 110: Pneumococcal Vaccine Market Size Gain ($ Million), 2024 – 2029, By Country

Table 111: Pneumococcal Vaccine Market Size Gain ($ Million), Segmentation By Product Type, 2024 – 2029

Table 112: Pneumococcal Vaccine Market Size Gain ($ Million), Segmentation By Route Of Administration, 2024 – 2029

Table 113: Pneumococcal Vaccine Market Size Gain ($ Million), Segmentation By Distribution Channel, 2024 – 2029

Table 114: Pneumococcal Vaccine Market Size Gain ($ Million), Segmentation By End User, 2024 – 2029

Table 115: Pneumococcal Vaccine Market Data Sources

List Of Figures

Figure 1: Global Pneumococcal Vaccine Market Segmentation By Product Type

Figure 2: Global Pneumococcal Vaccine Market Segmentation By Route of Administration

Figure 3: Global Pneumococcal Vaccine Market Segmentation By Distribution Channel

Figure 4: Global Pneumococcal Vaccine Market Segmentation By End User

Figure 5: Global Pneumococcal Vaccine Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Figure 6: Pneumococcal Vaccine Market, Historic, 2019 – 2024, $ Million

Figure 7: Pneumococcal Vaccine Market, Forecast, 2024 – 2029, 2034F, $ Million

Figure 8: Global Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 9: Global Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 10: Global Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 11: Global Pneumococcal Vaccine Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 12: Global Pneumococcal Vaccine Market, Sub-Segmentation Of Pneumococcal Conjugate Vaccines (PCVs), By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 13: Global Pneumococcal Vaccine Market, Sub-Segmentation Of Pneumococcal Polysaccharide Vaccine (PPV), By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 14: Pneumococcal Vaccine Market, By Region, Historic and Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 15: Pneumococcal Vaccine Market, By Country, Historic and Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 16: Asia-Pacific Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 17: Asia-Pacific Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 18: Asia-Pacific Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 19: China Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 20: China Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 21: China Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 22: India Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 23: India Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 24: India Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 25: Japan Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 26: Japan Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 27: Japan Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 28: Australia Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 29: Australia Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 30: Australia Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 31: Indonesia Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 32: Indonesia Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 33: Indonesia Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 34: South Korea Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 35: South Korea Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 36: South Korea Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 37: Western Europe Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 38: Western Europe Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 39: Western Europe Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 40: UK Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 41: UK Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 42: UK Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 43: Germany Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 44: Germany Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 45: Germany Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 46: France Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 47: France Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 48: France Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 49: Italy Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 50: Italy Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 51: Italy Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 52: Spain Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 53: Spain Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 54: Spain Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 55: Eastern Europe Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 56: Eastern Europe Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 57: Eastern Europe Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 58: Russia Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 59: Russia Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 60: Russia Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 61: North America Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 62: North America Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 63: North America Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 64: USA Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 65: USA Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 66: USA Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 67: Canada Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 68: Canada Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 69: Canada Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 70: South America Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 71: South America Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 72: South America Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 73: Brazil Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 74: Brazil Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 75: Brazil Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 76: Middle East Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 77: Middle East Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 78: Middle East Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 79: Africa Pneumococcal Vaccine Market, Segmentation By Product Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 80: Africa Pneumococcal Vaccine Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 81: Africa Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 82: Global Pneumococcal Vaccine, Key Competitor Estimated Market Shares, 2023, Percentage (%)

Figure 83: Pfizer Inc – Financial Overview, 2019 – 2023, $ Billion

Figure 84: Merck & Co., Inc – Financial Overview, 2019 – 2023, $ Billion

Figure 85: GlaxoSmithKline plc – Financial Overview, 2019 – 2023, $ Billion

Figure 86: Geographic Regions Covered

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

Discover key trends and market dynamics in the Mycobacterium Tuberculosis Market with 2025 insights from The Business Research Company.

CAR-T Therapy Market 2021 - By Target Antigen (CD19, CD22, BCMA), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma), And By ...

Pharmaceutical Drugs Market 2024 – By Type (Cardiovascular Drugs, Dermatology Drugs, Gastrointestinal Drugs, Genito-Urinary Drugs, Hematology Drugs, Anti-Infective Drugs, Metabolic Disorder Drugs, Musculoskeletal Disorde...

Oncology Drugs Market 2023 – By Type (Lung Cancer, Pancreatic Cancer, Breast Cancer, Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Gastric Cancer, Kidney Cancer, Brain Tumor, Thyroid Cancer, Skin Cancer, Bladder Ca...

Dry Eye Medication Market 2021 - By Prescription Type (OTC Drugs, Prescription Drugs) By Drug Variation (Branded, Generic) By Type Of Product (Aqueous, Evaporative, Aqueous And Evaporative) By Distribution Channel (Hospi...

Genito-Urinary Drugs Global Market Report 2022 – By Type (Hormonal Contraceptives, Drugs For Benign Prostatic hypertrophy, Drugs For Infertility, Drugs For Erectile Dysfunction, Drugs For Urinary Incontinence And Overact...

Gastrointestinal Drugs Global Market Report 2022 – By Type (Antacids, Antiulcerants, Vitamin And Minerals, Antiobesity, Antiemetics And Antinauseants, Antidiarrhoeals), By Distribution Channel (Hospital Pharmacies, Retai...

Hematology Drugs Global Market Report 2022 – By Type (Blood Products, Anemia And Other Blood Disorder Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others), By Route Of Administrat...

Pneumococcal Vaccine Global Market Opportunities And Strategies To 2034

Pneumococcal Vaccine Global Market Opportunities And Strategies To 2034

Market Insights

Related Reports

Pneumococcal Vaccine Market Definition

Pneumococcal Vaccine Market Size

Pneumococcal Vaccine Market Drivers

Pneumococcal Vaccine Market Restraints

Pneumococcal Vaccine Market Trends

Opportunities And Recommendations In The Pneumococcal Vaccine Market

Pneumococcal Vaccine Market Segmentation

Pneumococcal Vaccine Market Competitive Landscape

Major Competitors are:

Other Competitors Include:

Table Of Contents

List Of Tables

List Of Figures

Advanced Therapy Medicinal Products Industry Poised for Rapid Expansion, Projected to Hit $104.43 Billion by 2029

Global Insights: Androgen Deprivation Therapy Market Expected to Surpass $10.49 Billion by 2029

2025 Anti-CD20 Monoclonal Antibodies Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

Future Projections: Anti-D Immunoglobulin Market to Reach $3.34 Billion by 2029 at 6.6% CAGR

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

Discover key trends and market dynamics in the Mycobacterium Tuberculosis Market with 2025 insights from The Business Research Company.

Central Nervous System Drugs Market 2021 - By Type (Multiple Sclerosis (MS), Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, Other CNS Drugs), By Distribution Channel (Ho...

CAR-T Therapy Market 2021 - By Target Antigen (CD19, CD22, BCMA), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma), And By ...

Pharmaceutical Drugs Market 2024 – By Type (Cardiovascular Drugs, Dermatology Drugs, Gastrointestinal Drugs, Genito-Urinary Drugs, Hematology Drugs, Anti-Infective Drugs, Metabolic Disorder Drugs, Musculoskeletal Disorde...

Oncology Drugs Market 2023 – By Type (Lung Cancer, Pancreatic Cancer, Breast Cancer, Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Gastric Cancer, Kidney Cancer, Brain Tumor, Thyroid Cancer, Skin Cancer, Bladder Ca...

Dry Eye Medication Market 2021 - By Prescription Type (OTC Drugs, Prescription Drugs) By Drug Variation (Branded, Generic) By Type Of Product (Aqueous, Evaporative, Aqueous And Evaporative) By Distribution Channel (Hospi...

Genito-Urinary Drugs Global Market Report 2022 – By Type (Hormonal Contraceptives, Drugs For Benign Prostatic hypertrophy, Drugs For Infertility, Drugs For Erectile Dysfunction, Drugs For Urinary Incontinence And Overact...

Gastrointestinal Drugs Global Market Report 2022 – By Type (Antacids, Antiulcerants, Vitamin And Minerals, Antiobesity, Antiemetics And Antinauseants, Antidiarrhoeals), By Distribution Channel (Hospital Pharmacies, Retai...

Hematology Drugs Global Market Report 2022 – By Type (Blood Products, Anemia And Other Blood Disorder Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others), By Route Of Administrat...

Frequently Asked Questions